Be Biopharma grabs $52m Series A

Be Biopharma, a developer of B cells as medicines, has secured $52 million in Series A financing.

Be Biopharma, a developer of B cells as medicines, has secured $52 million in Series A financing. Atlas Venture and RA Capital Management led the round with participation from Alta Partners, Longwood Fund and Takeda Ventures, Inc.

Source: Press Release